NCT06922851

Protein A Immunoadsorption in Dilated Cardiomyopathy (RPIA-DCM)

Protein A Immunoadsorption in Dilated Cardiomyopathy: A Prospective, Multicenter, Randomized Study to Evaluate Efficacy and Safety (PRIA-DCM)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a multicenter, dual-arm and randomized controlled clinical trial. Sixty patients with dilated cardiomyopathy and positive β1-adrenergic receptor autoantibodies were selected and randomly divided into an immunoadsorption group (receiving immunoadsorption therapy) and a control group in a 1:1 ratio. Changes in cardiac function, morphology and clinical outcomes were followed up and compared.

Conditions

• Dilated Cardiomyopathy (DCM)

Interventions

Type	Name	Description
PROCEDURE	Immunoadsorption	Immunoadsorption (IA) therapy using a protein A column for four consecutive days, plus immunoglobulin supplementation after IA

Timeline

• Start date: 2025-06-04
• Primary completion: 2026-12-31
• Completion: 2028-06-30
• First posted: 2025-04-11
• Last updated: 2025-06-04

Locations

1 site across 1 country: China